Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma

Norihiro Sato, Noriyoshi Fukushima, Hiroyuki Matsubayashi, Christine A. Iacobuzio-Donahue, Charles J. Yeo, Michael S Goggins

Research output: Contribution to journalArticle

Abstract

BACKGROUND. The p53-dependent G2/M checkpoint plays a key role in the maintenance of genomic integrity, thereby protecting cells from neoplastic progression. Reprimo, a gene involved in the p53-induced G2 cell cycle arrest, has been recently identified as a novel target for aberrant methylation in pancreatic and other cancers. The biological and clinical relevance of Reprimo methylation in pancreatic cancer was investigated. METHODS. The methylation status of Reprimo CpG island was analyzed by methylation-specific polymerase chain reaction in a large series of pancreatic cancers and was correlated with p53 mutation status, genetic instability (as measured by the fractional allelic loss), and clinicopathologic features. RESULTS. Aberrant methylation of Reprimo was identified in 60% (75 of 125) of pancreatic cancer xenografts and primary pancreatic adenocarcinomas. Reprimo methylation was also detectable in 30% (19 of 63) of pancreatic intraepithelial neoplasias (PanIN), known precursors to infiltrating carcinoma. Reprimo methylation was unrelated to the p53 mutation status and associated with the increased degree of genetic instability (P = .04). Furthermore, we found that patients with Reprimo methylation in their primary pancreatic cancers have significantly worse prognosis than those without Reprimo methylation (P = .007). In contrast, other methylation targets in pancreatic cancers (SPARC and CXCR4) did not correlate with prognosis. CONCLUSIONS. These results suggest that aberrant methylation of Reprimo is a common event in pancreatic carcinogenesis and is associated with genetic instability and unfavorable outcome after surgical resection.

Original languageEnglish (US)
Pages (from-to)251-257
Number of pages7
JournalCancer
Volume107
Issue number2
DOIs
StatePublished - Jul 15 2006

Fingerprint

Methylation
Adenocarcinoma
Pancreatic Neoplasms
G2 Phase Cell Cycle Checkpoints
Mutation
CpG Islands
Loss of Heterozygosity
Heterografts
Carcinogenesis
Maintenance
Carcinoma
Polymerase Chain Reaction

Keywords

  • Carcinogenesis
  • Methylation
  • Pancreas
  • Reprimo

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma. / Sato, Norihiro; Fukushima, Noriyoshi; Matsubayashi, Hiroyuki; Iacobuzio-Donahue, Christine A.; Yeo, Charles J.; Goggins, Michael S.

In: Cancer, Vol. 107, No. 2, 15.07.2006, p. 251-257.

Research output: Contribution to journalArticle

Sato, Norihiro ; Fukushima, Noriyoshi ; Matsubayashi, Hiroyuki ; Iacobuzio-Donahue, Christine A. ; Yeo, Charles J. ; Goggins, Michael S. / Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma. In: Cancer. 2006 ; Vol. 107, No. 2. pp. 251-257.
@article{8f5dad113439429387dc1ac97568900a,
title = "Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma",
abstract = "BACKGROUND. The p53-dependent G2/M checkpoint plays a key role in the maintenance of genomic integrity, thereby protecting cells from neoplastic progression. Reprimo, a gene involved in the p53-induced G2 cell cycle arrest, has been recently identified as a novel target for aberrant methylation in pancreatic and other cancers. The biological and clinical relevance of Reprimo methylation in pancreatic cancer was investigated. METHODS. The methylation status of Reprimo CpG island was analyzed by methylation-specific polymerase chain reaction in a large series of pancreatic cancers and was correlated with p53 mutation status, genetic instability (as measured by the fractional allelic loss), and clinicopathologic features. RESULTS. Aberrant methylation of Reprimo was identified in 60{\%} (75 of 125) of pancreatic cancer xenografts and primary pancreatic adenocarcinomas. Reprimo methylation was also detectable in 30{\%} (19 of 63) of pancreatic intraepithelial neoplasias (PanIN), known precursors to infiltrating carcinoma. Reprimo methylation was unrelated to the p53 mutation status and associated with the increased degree of genetic instability (P = .04). Furthermore, we found that patients with Reprimo methylation in their primary pancreatic cancers have significantly worse prognosis than those without Reprimo methylation (P = .007). In contrast, other methylation targets in pancreatic cancers (SPARC and CXCR4) did not correlate with prognosis. CONCLUSIONS. These results suggest that aberrant methylation of Reprimo is a common event in pancreatic carcinogenesis and is associated with genetic instability and unfavorable outcome after surgical resection.",
keywords = "Carcinogenesis, Methylation, Pancreas, Reprimo",
author = "Norihiro Sato and Noriyoshi Fukushima and Hiroyuki Matsubayashi and Iacobuzio-Donahue, {Christine A.} and Yeo, {Charles J.} and Goggins, {Michael S}",
year = "2006",
month = "7",
day = "15",
doi = "10.1002/cncr.21977",
language = "English (US)",
volume = "107",
pages = "251--257",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma

AU - Sato, Norihiro

AU - Fukushima, Noriyoshi

AU - Matsubayashi, Hiroyuki

AU - Iacobuzio-Donahue, Christine A.

AU - Yeo, Charles J.

AU - Goggins, Michael S

PY - 2006/7/15

Y1 - 2006/7/15

N2 - BACKGROUND. The p53-dependent G2/M checkpoint plays a key role in the maintenance of genomic integrity, thereby protecting cells from neoplastic progression. Reprimo, a gene involved in the p53-induced G2 cell cycle arrest, has been recently identified as a novel target for aberrant methylation in pancreatic and other cancers. The biological and clinical relevance of Reprimo methylation in pancreatic cancer was investigated. METHODS. The methylation status of Reprimo CpG island was analyzed by methylation-specific polymerase chain reaction in a large series of pancreatic cancers and was correlated with p53 mutation status, genetic instability (as measured by the fractional allelic loss), and clinicopathologic features. RESULTS. Aberrant methylation of Reprimo was identified in 60% (75 of 125) of pancreatic cancer xenografts and primary pancreatic adenocarcinomas. Reprimo methylation was also detectable in 30% (19 of 63) of pancreatic intraepithelial neoplasias (PanIN), known precursors to infiltrating carcinoma. Reprimo methylation was unrelated to the p53 mutation status and associated with the increased degree of genetic instability (P = .04). Furthermore, we found that patients with Reprimo methylation in their primary pancreatic cancers have significantly worse prognosis than those without Reprimo methylation (P = .007). In contrast, other methylation targets in pancreatic cancers (SPARC and CXCR4) did not correlate with prognosis. CONCLUSIONS. These results suggest that aberrant methylation of Reprimo is a common event in pancreatic carcinogenesis and is associated with genetic instability and unfavorable outcome after surgical resection.

AB - BACKGROUND. The p53-dependent G2/M checkpoint plays a key role in the maintenance of genomic integrity, thereby protecting cells from neoplastic progression. Reprimo, a gene involved in the p53-induced G2 cell cycle arrest, has been recently identified as a novel target for aberrant methylation in pancreatic and other cancers. The biological and clinical relevance of Reprimo methylation in pancreatic cancer was investigated. METHODS. The methylation status of Reprimo CpG island was analyzed by methylation-specific polymerase chain reaction in a large series of pancreatic cancers and was correlated with p53 mutation status, genetic instability (as measured by the fractional allelic loss), and clinicopathologic features. RESULTS. Aberrant methylation of Reprimo was identified in 60% (75 of 125) of pancreatic cancer xenografts and primary pancreatic adenocarcinomas. Reprimo methylation was also detectable in 30% (19 of 63) of pancreatic intraepithelial neoplasias (PanIN), known precursors to infiltrating carcinoma. Reprimo methylation was unrelated to the p53 mutation status and associated with the increased degree of genetic instability (P = .04). Furthermore, we found that patients with Reprimo methylation in their primary pancreatic cancers have significantly worse prognosis than those without Reprimo methylation (P = .007). In contrast, other methylation targets in pancreatic cancers (SPARC and CXCR4) did not correlate with prognosis. CONCLUSIONS. These results suggest that aberrant methylation of Reprimo is a common event in pancreatic carcinogenesis and is associated with genetic instability and unfavorable outcome after surgical resection.

KW - Carcinogenesis

KW - Methylation

KW - Pancreas

KW - Reprimo

UR - http://www.scopus.com/inward/record.url?scp=33745848467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745848467&partnerID=8YFLogxK

U2 - 10.1002/cncr.21977

DO - 10.1002/cncr.21977

M3 - Article

C2 - 16752411

AN - SCOPUS:33745848467

VL - 107

SP - 251

EP - 257

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -